Wonderful to see the FDA, TGA and Canadian regulatory authorities working together to approve a new treatment for refractory/ relapsed Chronic Lymphocytic Leukaemia (CLL). Acalabrutinib is a second-generation BTK (Bruton’s tyrosine kinase or tyrosine-protein kinase) and was shown to be more effective and more tolerable than usual treatments. We look forward to seeing this treatment made available in Australia. https://www.tga.gov.au/media-release/acalabrutinib-receives-tga-approval-cll-and-sll-cancers
making hope real for australians
in the fight against blood cancers
You have a blood cancer
Five little life-changing words that over 15,000 Australian men, women and little children will be told this year.
One day, we hope no one ever has to hear those five little words again.
Focus on new blood cancer treatment
Right now, cancer research is rapidly growing with the support and introduction of new technology into human genes. Just imagine a treatment that is tailored or personalised to match your type of cancer as well as your personal genetic profile. Well, it’s not a distant dream and it is certainly no research black hole as...
Read MoreAchievements
View achievementsAnnual reports
View reportsPatient stories
View storiesSnowdome's unique approach
Read our approachWhat is blood cancer?
Blood cancers are common genetic diseases, but not in the sense that they're conditions you inherit from your parents. Rather, blood cancers are caused by the genes.
Read More372
Patients
have gained access to new treatments with Snowdome support
20
Clinical Trials
have commenced with Snowdome infrastructure support
$25
Million
secured and directed to Snowdome prioritized projects
Snowdome in the news
-
-
Andrea grew up in Melbourne and has over 20 years experience in senior leadership positions working with organisations like Nike Australia. Andrea relocated to...
-
Kaz should have been snuggling into her newborn baby, gazing into her eyes as she fed but instead, she was being infused with chemotherapy....
